Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...
The new cost-based program leverages multiple available industry data sources, such as NADAC and PAC, to inform reimbursement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback